

Supplementary table 1 Primers for real-time PCR assays

ETV5	forward	5'-CAGCACACGGGTTCCAGTCAC-3'
	reverse	5'-TGGCAGTTAGGCACTTCTGAATCG3'
SKA1	forward	5'-AGAGGGGAGAGGGGCTGGAG-3'
	reverse	5'-GCGTCACCTTCCTGGCACATG3'
TRPV2	forward	5'-GATCGGCTCTTCAATGCGGTCT-3'
	reverse	5'-CGGTGAGGTACTTGCTGGTCTTG3'
SKA1(for CHIP)	forward	5'-AGGAAAGGACCCAGGCTTATCG3'
	reverse	5'-ACCGTACTGACTTGTCTTAGAGCG3'
TRPV2(for CHIP)	forward	5'-GGGCTGTCCACATCAGCTTCTCG3'
	reverse	5'-CAGGCTCCACCCACCC-3'

Supplementary table 2 The relationship between clinical factors and ETV5 expression

Clinicopathological factors	ETV5 expression		
	High	Low	P-value
<b>Gender</b>			
Male	36	29	0.542
Female	9	5	
<b>Age(y)</b>			
≤60	12	14	0.174
> 60	33	20	
<b>Tumor size</b>			
≤3cm	15	15	1
> 3cm	30	30	
<b>Metastasis*</b>			
Negative	28	29	0.024
Positive	17	5	
<b>TNM stage</b>			
0-II	30	30	0.026
III-IV	15	4	

\* Metastasis here includes lymph node metastasis and other organs metastasis.